Chinese Medical Journal

Papers
(The H4-Index of Chinese Medical Journal is 28. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Cancer statistics in China and United States, 2022: profiles, trends, and determinants1303
Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 20201243
Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7)475
Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective study454
Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus-related coronavirus model213
Recommendations for respiratory rehabilitation in adults with coronavirus disease 2019134
Lung transplantation as therapeutic option in acute respiratory distress syndrome for coronavirus disease 2019-related pulmonary fibrosis120
From NAFLD to MAFLD: a “redefining” moment for fatty liver disease70
Nanjing consensus on methodology of washed microbiota transplantation67
Effectiveness of glucocorticoid therapy in patients with severe coronavirus disease 2019: protocol of a randomized controlled trial64
Clinical application and mechanism of traditional Chinese medicine in treatment of lung cancer63
Interpretations of “Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7)”53
A guide to human microbiome research: study design, sample collection, and bioinformatics analysis53
Gut hormones in microbiota-gut-brain cross-talk53
MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy52
Pneumoconiosis: current status and future prospects51
Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical tria46
Climate change, air pollution, and allergic respiratory diseases: a call to action for health professionals37
Blood-retinal barrier as a converging pivot in understanding the initiation and development of retinal diseases35
2022 Chinese national clinical practice guideline on Helicobacter pylori eradication treatment34
Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild t33
A confirmed asymptomatic carrier of 2019 novel coronavirus33
Reinfection rates among patients previously infected by SARS-CoV-2: systematic review and meta-analysis33
Prevention and control of HIV/AIDS in China: lessons from the past three decades32
Gut microbiota dysbiosis in preeclampsia patients in the second and third trimesters30
China artificial joint annual data report30
Cerebral amyloid angiopathy-related inflammation: current status and future implications30
Clinical practice guidelines for sentinel lymph node biopsy in patients with early-stage breast cancer: Chinese Society of Breast Surgery (CSBrS) practice guidelines 202129
0.046931028366089